Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers-Reference-Cited by-同舟云学术

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Published:2016-07 Issue:7 Volume:27 Page:1286-1291
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Drilon A.,Bergagnini I.,Delasos L.,Sabari J.,Woo K.M.,Plodkowski A.,Wang L.,Hellmann M.D.,Joubert P.,Sima C.S.,Smith R.,Somwar R.,Rekhtman N.,Ladanyi M.,Riely G.J.,Kris M.G.

Funder

National Institutes of Health/National Cancer Institute Cancer Center Support

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/7/1286/16698226/mdw163.pdf

Reference19 articles.

1. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update;Masters;J Clin Oncol,2015

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol,2011

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations;BMC Cancer;2024-08-03

3. RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future;Drugs;2024-07-13

4. Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis;Heliyon;2024-07

5. Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion;OncoTargets and Therapy;2024-06